Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sunshine Bill Trade-Off: Stronger Pre-emption Would Mean More Disclosure

Executive Summary

Increased pre-emption under the Physician Payment Sunshine Act is possible if the federal law is expanded to include all or most provisions under state disclosure laws, Senate Finance Committee Investigative Counsel Christopher Armstrong said at the National Disclosure Summit in Washington, D.C

You may also be interested in...



States Will Watch How Industry Payments To Docs Change With Sunshine Act

State regulators will be watching for changes in the payments pharmaceutical companies make to physicians once federal legislation is passed requiring disclosure, New York State Medicaid Inspector General Jim Sheehan said at the National Disclosure Summit

States Will Watch How Industry Payments To Docs Change With Sunshine Act

State regulators will be watching for changes in the payments pharmaceutical companies make to physicians once federal legislation is passed requiring disclosure, New York State Medicaid Inspector General Jim Sheehan said at the National Disclosure Summit

Sen. Grassley Clarifies Remarks On CME Disclosure: No Need To “Forgo” Independence

Earlier comments not reflective of "sunshine" legislation, but of hypothetical changes to third-party reporting requirements.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050826

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel